Investors
Agios is a biopharmaceutical company passionately committed to applying our scientific leadership in the field of cellular metabolism to transform the lives of patients with cancer and rare genetic diseases.
Nasdaq: AGIO
    
2017 Press Releases
Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
Jun 24, 2017
New Data from Phase 1/2 Trial of Oral IDHIFA® (enasidenib) Demonstrate Durable Complete Responses in Patients with IDH2 Mutant Relapsed or Refractory AML
Jun 24, 2017
Agios Announces Updated Data from Fully Enrolled DRIVE PK Study Demonstrating AG-348’s Potential as the First Disease-modifying Treatment for Patients with Pyruvate Kinase Deficiency
Jun 06, 2017
Updated Data from Phase 1 Trial of Oral IDHIFA® (enasidenib) Demonstrate Complete Responses and Duration of Response in Patients with Relapsed or Refractory AML and an IDH2 Mutation
Jun 03, 2017
Agios Presents Phase 1 Data from Dose-Escalation and Expansion Cohorts of AG-120 (Ivosidenib) in Patients with Previously Treated IDH1 Mutant Positive Cholangiocarcinoma
May 31, 2017
Agios Appoints David Scadden, M.D., to the Board of Directors
May 18, 2017
Agios to Present Updated Clinical Data from PKR Activator AG-348 at EHA
May 17, 2017
Agios to Present New Clinical Data from its IDH Programs at ASCO
May 04, 2017
Agios Reports First Quarter 2017 Financial Results
Apr 28, 2017
Agios Announces Closing of Over-Allotment Option in Public Offering
Apr 27, 2017
Agios and Aurigene Enter into Exclusive License Agreement for Novel Small Molecules for Cancer Metabolism Target
Apr 27, 2017
Agios to Webcast Conference Call of First Quarter 2017 Financial Results on May 4, 2017
Apr 26, 2017
Agios Announces Exercise of Over-Allotment Option in Public Offering
Apr 24, 2017
Agios Announces Closing of Public Offering
Apr 18, 2017
Agios Announces Pricing of $250 Million Public Offering of Common Stock
Apr 17, 2017
Agios Announces Proposed Offering of Common Stock
Mar 30, 2017
Agios to Present at the 16th Annual Needham Healthcare Conference on Tuesday April 4, 2017
Mar 13, 2017
Agios Announces MTAP Pathway Research Program as Development Program and Development Candidate Under Master Research and Collaboration Agreement with Celgene
Mar 01, 2017
FDA Accepts New Drug Application and Grants Priority Review for Enasidenib in Relapsed or Refractory AML with an IDH2 Mutation
Feb 28, 2017
Agios to Present at the Cowen and Company 37th Annual Health Care Conference on Monday, March 6, 2017
Feb 16, 2017
Agios Reports Fourth Quarter and Full Year 2016 Financial Results and Highlights Key 2017 Milestones
Feb 09, 2017
Agios to Webcast Conference Call of Fourth Quarter and Full Year 2016 Financial Results on February 16, 2017
Jan 09, 2017
Agios Announces Key Upcoming Milestones to Support Evolution to a Commercial Stage Biopharmaceutical Company in 2017
Jan 03, 2017
Agios Appoints Ian Clark to Board of Directors
Jan 03, 2017
Agios to Present at the 35th Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2017